Press

Algernon Pharmaceuticals Completes Manufacturing of DMT, Appoints UK Stroke Experts for Phase 2

Dec 8 • 4 min read

Algernon Pharmaceuticals Inc. (CSE: AGN), a clinical stage pharmaceutical development company is pleased to announce that it has completed the manufacturing of its clinical grade supply of AP-188 (“N,N-Dimethyltryptamine or DMT”) at Canadian manufacturer Dalton Pharma Services. The Company believes it has produced a sufficient supply of cGMP DMT to complete its planned Phase 1…

Mycotopia and Ei.Ventures sign LOI to Explore Merger and Formation of PSLY.COM, a $360 Million Transaction, And Will Apply To List Shares On NASDAQ

Dec 7 • 5 min read

Mycotopia Therapies Inc. (OTC Pink: TPIA), a biopharma company focused on research, technology, and the development of medical psychedelics, announced today it has entered into a letter of intent regarding a potential acquisition of botanical psilocybin pioneer, Ei.Ventures. When a definitive agreement is reached, the combined companies intend to pool their resources to develop regulatory approved, plant-derived,…

PsyBio Therapeutics Successfully Completes First Pre-IND Meeting with FDA

Dec 7 • 3 min read

PsyBio Therapeutics Corp. (TSXV: PSYB), an intellectual property driven biotechnology company focused upon discovery and development of new, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health, today announced the successful completion of its initial pre-Investigational New Drug application meeting with the United States Food and Drug Administration as part of the regulatory submission process. “PsyBio was created…

Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs

Dec 6 • 4 min read

Mydecine Innovations Group (NEO: MYCO), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced it has filed a full patent application covering multiple families of psilocin analogs. The application includes solutions to directly address further precision in delivery control and shelf stabilization of psilocin, psilocybin’s…

Awakn Life Sciences Strengthens Executive Leadership Team

Dec 3 • 2 min read

Awakn Life Sciences Corp. (NEO: AWKN), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, announced today the execution of an agreement to appoint Kate Butler as new Chief Financial Officer, and Jonathan Held, current Chief Financial Officer, to transition to Awakn’s Chief Business Officer. Under the terms of the…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441